Degradation of BMS-753493, a novel epothilone folate conjugate anticancer agent

Drug Development and Industrial Pharmacy

Volumn 39, Issue 9, 2013, Pages 1315-1327

  Gokhale, Madhushree ^a   Thakur, Ajit ^a   Rinaldi, Frank ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Degradation; Epothilone folate conjugate; LC SPE NMR; Parenteral; Stability

Indexed keywords

ANTINEOPLASTIC AGENT; BMS 753493; EPOTHILONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONJUGATE; DEGRADATION KINETICS; DRUG DEGRADATION; DRUG HYDROLYSIS; DRUG STABILITY; HETERONUCLEAR MULTIPLE BOND CORRELATION; IONIC STRENGTH; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PH;

ANTIMETABOLITES, ANTINEOPLASTIC; BUFFERS; DRUG STABILITY; DRUGS, INVESTIGATIONAL; EPOTHILONES; FOLIC ACID; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; KINETICS; MOLECULAR STRUCTURE; TEMPERATURE;

EID: 84881136041     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.728226     Document Type: Article

References (24)

1. Georg GI, Harriman GCB, Vander Velde DG, Boge TC, Cheruvallath ZS, Datta A, et al. (1995). The medicinal chemistry of Taxol: chemistry, structure-activity relationships and conformational analysis: Taxane anticancer agents: Basic science and current status. American Chemical Society; Washington DC:217-232.
2. Boge TC, Himes RH, Vander Velde DG, Georg GI. (1994). The effect of the aromatic rings of taxol on biological activity and solution conformation: synthesis and evaluation of saturated taxol and taxotere analogues. J Med Chem, 37:3337-3343. (Pubitemid 24325047)
3. Rowinsky EK. (1997). The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med, 48:353-374. (Pubitemid 27101837)
4. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J et al. (1995). Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res, 55:2325-2333.
5. Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B et al. (2000). A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA, 97:2904-2909. (Pubitemid 30159270)
6. Feyen F, Cachoux F, Gertsch J, Wartmann M, Altmann KH. (2008). Epothilones as lead structures for the synthesis-based discovery of new chemotypes for microtubule stabilization. Acc Chem Res, 41:21-31.
7. Lowand PS, Henne WA. (2008). Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res, 41:120-129.
8. Hilgenbrinkand A, Low PS. (2005). Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci, 94:2135-2146. (Pubitemid 41665275)
9. Ladino CA, Chari RV, Bourret LA, Kedersha NL, Goldmacher VS. (1997). Folate-maytansinoids: target-selective drugs of low molecular weight. Int J Cancer, 73:859-864. (Pubitemid 127483041)
10. Leamon CP. (2008). Folate-targeted drug strategies for the treatment of cancer. Curr Opin Investig Drugs, 9:1277-1286.
11. Rinaldi F. (2007). The application of LC-SPE-cryoflowNMR spectroscopy in pharmaceutical development. American Drug Discovery, 3:33.
12. Palmer III AG, Wright PE, Rance M. (1991). Measurement of relaxation time constants for methyl groups by proton-detected heteronuclear NMR spectroscopy. Chemical Physics Letters, 185:41-46.
13. Schleucher J, Schwendinger M, Sattler M, Schmidt P, Schedletzky O, Glaser SJ et al. (1994). A general enhancement scheme in heteronuclear multidimensional NMR employing pulsed field gradients. J Biomol NMR, 4:301-306.
14. Kay LE, Keifer P, Saarinen T. (1992). Pure absorption gradient enhanced heteronuclear single quantum correlation spectroscopy with improved sensitivity. J Am Chem Soc, 114:10663-10665.
15. Baxand A, Davis DG. (1985). MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy. J Magn Reson, 65:355-360.
16. Kuehl PJ, Hoye WL, Myrdal PB. (2006). Preformulation studies on imexon. Drug Dev Ind Pharm, 32:687-697. (Pubitemid 44181197)
17. Tarbelland SD, Noble PJ. (1950). Acid-catalyzed ring-opening reactions of some unsymmetrical ethyleneimine derivatives. J Am Chem Soc, 72:2657-2661.
18. March J. (1985). Advanced organic chemistry: reactions, mechanims and structure. New York: John Wiley and Sons.
19. Connors KA. (1990). Chemical kinetics: the study of reaction rates in solution. New York: VCH Publishers Inc.
20. Fassbergand J, Stella VJ. (1992). A kinetic and mechanistic study of the hydrolysis of Camptothecin and some analogues. J Pharm Sci, 81:676-684. (Pubitemid 23006796)
21. Hanson BA, Schowen RL, Stella VJ. (2003). A mechanistic and kinetic study of the E-ring hydrolysis and lactonization of a novel phosphoryloxymethyl prodrug of camptothecin. Pharm Res, 20:1031-1038. (Pubitemid 36774274)
22. Denora N, Potts BC, Stella VJ. (2007). A mechanistic and kinetic study of the beta-lactone hydrolysis of Salinosporamide A (NPI-0052), a novel proteasome inhibitor. J Pharm Sci, 96:2037-2047. (Pubitemid 47280100)
23. Kaiserand ET, Kezdy FJ. (1976). Hydrolysis of cyclic esters. Prog Bioorg Chem, 4:239-267.
24. Jumaa A, Carlson B, Chimilio L, Silchenko S, Stella VJ. (2004). Kinetics and mechanism of degradation of epothilone-D: an experimental anticancer agent. J Pharm Sci, 93:2953-2961. (Pubitemid 39657799)